Organigram (OGI) Competitors

Iovance Biotherapeutics (NASDAQ:IOVA) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Which has more volatility & risk, IOVA or OGI?

Iovance Biotherapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.

Does the MarketBeat Community prefer IOVA or OGI?

Iovance Biotherapeutics received 379 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 74.16% of users gave Iovance Biotherapeutics an outperform vote while only 70.71% of users gave Organigram an outperform vote.

Company	Underperform	Outperform
Iovance Biotherapeutics	Outperform Votes 577 74.16%	Underperform Votes 201 25.84%
Organigram	Outperform Votes 198 70.71%	Underperform Votes 82 29.29%

Do analysts prefer IOVA or OGI?

Iovance Biotherapeutics currently has a consensus target price of $13.30, indicating a potential upside of 475.76%. Given Iovance Biotherapeutics' higher probable upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Organigram.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Organigram	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is IOVA or OGI more profitable?

Organigram has a net margin of -31.69% compared to Iovance Biotherapeutics' net margin of -451.25%. Organigram's return on equity of -8.59% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-451.25%	-58.43%	-45.48%
Organigram	-31.69%	-8.59%	-6.54%

Which has higher valuation and earnings, IOVA or OGI?

Organigram has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$212.68M	3.63	-$444.04M	-$1.24	-1.86
Organigram	$194.09M	1.01	-$33.39M	$0.10	14.70

Does the media refer more to IOVA or OGI?

In the previous week, Iovance Biotherapeutics had 37 more articles in the media than Organigram. MarketBeat recorded 39 mentions for Iovance Biotherapeutics and 2 mentions for Organigram. Organigram's average media sentiment score of 1.71 beat Iovance Biotherapeutics' score of 0.06 indicating that Organigram is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	36 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organigram	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do insiders & institutionals believe in IOVA or OGI?

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 34.6% of Organigram shares are held by institutional investors. 10.3% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 0.1% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Iovance Biotherapeutics beats Organigram on 10 of the 18 factors compared between the two stocks.